Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
← catalyst calendarNCT07484217 · readout ≤ 864 d
Sponsored by Axsome Therapeutics, Inc. (industry) · AXSM — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
508estimated
Sites
40
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-23 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
- Drug: Solriamfetol 150 MG
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime from randomization to relapse of depressive symptoms
measured Up to 24 weeks.
Permalink · AXSM's whole pipeline · Catalyst calendar · Every registered study · What changed